CSPC Innovation Pharmaceutical Co., Ltd. (300765.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 43.38

From 52W high−22.43%

Volume16.79M

Market capCNY 63.54B

P/E (TTM)−263.5x

P/S (TTM)26.2x

Div yield—

Key dataSep 18, 2026

Open

CNY 43.38

From 52W high

−22.43%

Volume

16.79M

Market cap

CNY 63.54B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−189.1x

P/E (TTM)

−263.5x

RSI (14)

52.6

MomentumView details →

1D Return

−7.67%

YTD Return

+21.65%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−263.5x

EV/EBITDA

−189.1x

EV/Sales

26.0x

P/S (TTM)

26.2x

P/B (TTM)

16.1x

ProfitabilityView details →

Gross Margin

38.84%

Net Margin

−13.11%

EBITDA Margin

−13.75%

ROE (TTM)

−11.95%

ROA (TTM)

−4.96%

Asset Turnover

0.38x

GrowthView details →

Revenue YoY

+21.87%

EPS YoY

—

FCF YoY

−0.36%

Revenue CAGR 3Y

−6.34%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−7.67%

YTD Return

+21.65%

1Y Return

−13.91%

RSI (14)

52.6

vs 50D SMA

+4.61%

vs 200D SMA

+26.18%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.00x

Quick Ratio

0.83x

Div Yield

—

Div Rate

—

Div Growth 1Y

−93.75%

EarningsView details →

EPS (Actual)

CNY 0.97

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−0.94%

Financials snapshotView financials →

Revenue (TTM)

2.35B

Net Income (TTM)

−308.08M

Op. CF (TTM)

−288.41M

Next earningsOct 28, 2026 →

Latest newsMore news →

CSPC Innovation's controlling subsidiary Giant Stone Biotech presented Phase I/II clinical data for SYS6010 combined with enlonstobart in advanced non-small cell lung cancer at the 2026 World Conference on Lung Cancer.6d ago

Shijiazhuang Pharma Innovation's controlled subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its SYH2092 injection in China.24d ago

Similar companies

国瓷材料300285.SZ 君正股份300223.SZ 云南锗业002428.SZ 中国稀土000831.SZ 科伦药业002422.SZ 中联重科000157.SZ Find similar companies →

Latest newsMore news →

CSPC Innovation's controlling subsidiary Giant Stone Biotech presented Phase I/II clinical data for SYS6010 combined with enlonstobart in advanced non-small cell lung cancer at the 2026 World Conference on Lung Cancer.6d ago Shijiazhuang Pharma Innovation's controlled subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its SYH2092 injection in China.24d ago CSPC Pharmaceutical Group's subsidiary CSPC Innovation Pharmaceutical reported a net profit of 1.261 billion yuan for the first half of 2026, turning around from a loss of 2.75 million yuan a year earlier, with revenue up 208.7% year-on-year to 3.24 billion yuan.34d ago